Company / Cash & Equivalents
NewAmsterdam Pharma Co N.V. Cash & Equivalents History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$490.0M
FY2025
5-year range
$340.4M / $771.7M
FY2023-FY2025
Trend
-36.5%
vs FY2024
Sector context
#42 of 208
Health Care
What the data says
NewAmsterdam Pharma Co N.V.'s cash & equivalents of $490M is higher than 80% of companies in the Health Care sector (FY2025). Improved from $340M to $490M over the past 2 years.
Based on SEC 10-K filings.
$490M in FY2025. Top quartile in the Health Care sector.
Improved from $340M to $490M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 208This company $490.0M Sector average $694.3M
▼
-29.4% below sector average
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 36.5% year-over-year.
- Ranks #42 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $490.0M | -36.5% |
| FY2024 | $771.7M | +126.7% |
| FY2023 | $340.4M | - |
| FY2022 | - | - |
| FY2021 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026